Nonsurgical repigmentation therapies in vitiligo - Meta-analysis of the literature

被引:198
作者
Njoo, MD
Spuls, PI
Bos, JD
Westerhof, W
Bossuyt, PMM
机构
[1] Univ Amsterdam, Acad Med Ctr, Netherlands Inst Pigmentary Disorders, Inst Wetenschappelyk Onderzoek Bldg, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1001/archderm.134.12.1532
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To assess the effectiveness and safety of nonsurgical repigmentation therapies in localized and generalized vitiligo by means of a meta-analysis. Data Sources: Computerized searches of bibliographic databases, a complementary manual literature search, and contacts with researchers and pharmaceutical firms. Study Selection: Predefined selection criteria were applied to both randomized and nonrandomized controlled trials. Data Extraction: Two investigators independently assessed the articles for inclusion. When there was a disagreement, a third investigator was consulted. Data Synthesis: Sixty-three studies were found on therapies for localized vitiligo. Of these, 10 of 11 randomized controlled trials and 29 of 110 patient series were included. One hundred seventeen studies on therapies for generalized vitiligo were found. Of these, 10 of 22 randomized controlled trials and 46 of 231 patient series were included. Among randomized controlled trials on localized vitiligo, the pooled odds ratio vs placebo was significant for topical class 3 corticosteroids (14.32; 95% confidence interval [CI], 2.45-83.72). In the patient series, topical class 3 and class 4 corticosteroids carried the highest mean success rates (56% [95% CI, 50%-62%] and 55% [95% CI, 49%-61%], respectively). Side effects were reported mostly with topical psoralen and intralesional and class 4 corticosteroids. In the randomized controlled trials on generalized vitiligo, the odds ratio vs placebo was significant for oral methoxsalen plus sunlight (23.37; 95% CI, 1.33-409.93), oral psoralen plus sunlight (19.87; 95% CI, 2.37-166.32), and oral trioxsalen plus sunlight (3.75; 95% CI, 1.24-11.29). In the series, the highest mean success rates were achieved with narrowband UV-B (63%; 95% CI, 50%-76%), broadband UV-B (57%; 95% CI, 29%-82%), and oral methoxsalen plus UV-A therapy (51%; 95% CI, 46%-56%). Oral methoxsalen plus W-A was associated with the highest rates of side effects. No side effects were reported with W-B therapy. Conclusions: Class 3 corticosteroids and UV-B therapy are the most effective and safest therapies for localized and for generalized vitiligo, respectively.
引用
收藏
页码:1532 / 1540
页数:9
相关论文
共 57 条
[1]   AN APPROACH TO THE TREATMENT OF VITILIGO BY KHELLIN [J].
ABDELFATTAH, A ;
ABOULENEIN, MN ;
WASSEL, GM ;
ELMENSHAWI, BS .
DERMATOLOGICA, 1982, 165 (02) :136-140
[2]   The failure of L-phenylalanine and UVA in the treatment of vitiligo [J].
AlKhawajah, MM .
JOURNAL OF DERMATOLOGICAL TREATMENT, 1996, 7 (03) :181-182
[3]  
ALTMAN DG, 1997, PRACTICAL STAT MED R, P268
[4]   A COMPARISON OF RESULTS OF METAANALYSES OF RANDOMIZED CONTROL TRIALS AND RECOMMENDATIONS OF CLINICAL EXPERTS - TREATMENTS FOR MYOCARDIAL-INFARCTION [J].
ANTMAN, EM ;
LAU, J ;
KUPELNICK, B ;
MOSTELLER, F ;
CHALMERS, TC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (02) :240-248
[5]   VITILIGO THERAPY WITH ORAL AND TOPICAL PHENYLALANINE WITH UVA EXPOSURE [J].
ANTONIOU, C ;
SCHULPIS, H ;
MICHAS, T ;
KATSAMBAS, A ;
FRAJIS, N ;
TSAGARAKI, S ;
STRATIGOS, J .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1989, 28 (08) :545-547
[6]   GUIDELINES FOR THE TREATMENT OF VITILIGO [J].
ANTONIOU, C ;
KATSAMBAS, A .
DRUGS, 1992, 43 (04) :490-498
[7]   TREATMENT OF VITILIGO WITH TOPICAL CORTICOSTEROIDS - LIGHT AND ELECTRON-MICROSCOPIC STUDIES [J].
BLEEHEN, SS .
BRITISH JOURNAL OF DERMATOLOGY, 1976, 94 :43-50
[8]   Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo [J].
Buckley, DA ;
Rogers, S .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1996, 21 (01) :43-45
[9]   DOUBLE-BLIND TRIAL OF 0.05 PERCENT CLOBETASOL PROPRIONATE IN TREATMENT OF VITILIGO [J].
CLAYTON, R .
BRITISH JOURNAL OF DERMATOLOGY, 1977, 96 (01) :71-73
[10]   The relation between systematic reviews and practice guidelines [J].
Cook, DJ ;
Greengold, NL ;
Ellrodt, AG ;
Weingarten, SR .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (03) :210-216